These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1043 related articles for article (PubMed ID: 30975694)
1. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694 [TBL] [Abstract][Full Text] [Related]
2. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer. Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405 [No Abstract] [Full Text] [Related]
3. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929 [TBL] [Abstract][Full Text] [Related]
4. N Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901 [TBL] [Abstract][Full Text] [Related]
5. Z-guggulsterone induces PD-L1 upregulation partly mediated by FXR, Akt and Erk1/2 signaling pathways in non-small cell lung cancer. Tian H; Gui Y; Wei Y; Shang B; Sun J; Ma S; You W; Jiang S Int Immunopharmacol; 2021 Apr; 93():107395. PubMed ID: 33529916 [TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy. Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230 [TBL] [Abstract][Full Text] [Related]
7. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
8. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694 [TBL] [Abstract][Full Text] [Related]
9. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer. Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072 [TBL] [Abstract][Full Text] [Related]
11. PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. He Y; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Yu H; Zhou C; Hirsch FR Med Sci Monit; 2017 Mar; 23():1208-1216. PubMed ID: 28275222 [TBL] [Abstract][Full Text] [Related]
12. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy. Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532 [TBL] [Abstract][Full Text] [Related]
13. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients. El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185 [TBL] [Abstract][Full Text] [Related]
14. Programmed death-1 receptor (PD-1) and PD-ligand-1 (PD-L1) expression in non-small cell lung cancer and the immune-suppressive effect of anaerobic glycolysis. Giatromanolaki A; Koukourakis IM; Balaska K; Mitrakas AG; Harris AL; Koukourakis MI Med Oncol; 2019 Jul; 36(9):76. PubMed ID: 31342270 [TBL] [Abstract][Full Text] [Related]
15. Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8 Munari E; Marconi M; Querzoli G; Lunardi G; Bertoglio P; Ciompi F; Tosadori A; Eccher A; Tumino N; Quatrini L; Vacca P; Rossi G; Cavazza A; Martignoni G; Brunelli M; Netto GJ; Moretta L; Zamboni G; Bogina G Front Immunol; 2021; 12():680973. PubMed ID: 34122444 [TBL] [Abstract][Full Text] [Related]
16. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008 [TBL] [Abstract][Full Text] [Related]
17. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer. Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750 [TBL] [Abstract][Full Text] [Related]
18. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion. Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552 [TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC). Jiang L; Su X; Zhang T; Yin X; Zhang M; Fu H; Han H; Sun Y; Dong L; Qian J; Xu Y; Fu X; Gavine PR; Zhou Y; Tian K; Huang J; Shen D; Jiang H; Yao Y; Han B; Gu Y Oncotarget; 2017 Apr; 8(16):26845-26857. PubMed ID: 28460468 [TBL] [Abstract][Full Text] [Related]
20. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]